劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$
![]()
Shorts got to pay interest on delisting stocks, no free ticket out of here since no bankruptcy, liquidation isn't 100% so shorts are stuck and getting nervous. Reason why they try to convince you shares are worthless with delisting, insolvency, dissolution talk, that was concerning Roche/LMDX deal, not the many other subsidiaries. ElectraDX is a project Ron_Z is working on. Remember CORZ or HERTZ, don't let these bears ruin your hopes. secured and unsecured have been paid...
3
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$ Roche still has 5.5B from '24 for M&A. Confirmed by FTI CONSULTING ( $FTI Consulting (FCN.US)$) lady I spoke to yesterday it's a restructuring. I bet Roche is gluing all the pieces together to streamline operations. 👍. Confirmed by Trading 212 there is uncertainty but that it is an acquisitions event. My guess is that the 5.5B they never spent was being used for a NDA. dissolution doesn't mean our shares necessarily go away in this situation. Also if we get screwed we can mos...
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/73431851/20250214/1739542279491-random6018-73431851-android-org.png/thumb?area=100&is_public=true)
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/73431851/20250214/1739542282185-random6597-73431851-android-org.png/thumb?area=100&is_public=true)
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/73431851/20250214/1739542283210-random8639-73431851-android-org.png/thumb?area=100&is_public=true)
5
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$
The integration of LumiraDx with Roche's navify digital solutions can be approached in several ways, based on the capabilities and objectives of both companies as outlined in recent news and company statements:
Point of Care (POC) Data Integration:
navify Analytics for POC: With the acquisition, LumiraDx's point-of-care testing devices could be integrated into Roche's navify Analytics suite. This would allow for real-time data collection and analysis from LumiraDx's portabl...
The integration of LumiraDx with Roche's navify digital solutions can be approached in several ways, based on the capabilities and objectives of both companies as outlined in recent news and company statements:
Point of Care (POC) Data Integration:
navify Analytics for POC: With the acquisition, LumiraDx's point-of-care testing devices could be integrated into Roche's navify Analytics suite. This would allow for real-time data collection and analysis from LumiraDx's portabl...
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/73431851/20250214/1739544356785-random9959-73431851-android-org.png/thumb?area=100&is_public=true)
10
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$ SilentStockInvestor on Stocktwits had asked if anybody read the dissolution PDF. At first I scoffed it off old news but then I read into it a bit more.
@BadPaint Columbia is going through a bidding war currently check this out.
2nd dash multiple parties involved, improve bids....🌙
@BadPaint Columbia is going through a bidding war currently check this out.
2nd dash multiple parties involved, improve bids....🌙
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/73431851/20250129/1738094165637-random5555-73431851-android-org.png/thumb?area=100&is_public=true)
6
1
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$ @BadPaint revisiting your Bill Gates post about him not selling his shares. It was announced while Lumiradx was on expert market I believe. Now I will say this, all the institutions that sold could have sold prior to expert market and bought back in during expert through an offshore entity. Zwanziger Ventures LLC perhaps? Can you dig more into Senvest for us?
Off topic here a bit however I found this intriguing that Cobas was introduced in '94 however Roche only started divi...
Off topic here a bit however I found this intriguing that Cobas was introduced in '94 however Roche only started divi...
6
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$fiercebiotech.c...
So, let me get this straight....
$ROCHE HOLDING AG (RHHBY.US)$ a 350B company has 10B to allocate/year for acquisitions. Only had 3 acquisitions last year
us
$Poseida Therapeutics(Delisted) (PSTX.US)$
&
Carmot
and have the AUDACITY to keep us in the dark for so long after inserting directors and pulling all the shennanigans they can. Most of the shareholders here would accept 10 a share. I won't accept less than 25.00 for this now.
So, let me get this straight....
$ROCHE HOLDING AG (RHHBY.US)$ a 350B company has 10B to allocate/year for acquisitions. Only had 3 acquisitions last year
us
$Poseida Therapeutics(Delisted) (PSTX.US)$
&
Carmot
and have the AUDACITY to keep us in the dark for so long after inserting directors and pulling all the shennanigans they can. Most of the shareholders here would accept 10 a share. I won't accept less than 25.00 for this now.
4
2
劳瘁的米德尔顿
reacted to
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/73431851/20250113/1736741806054-random31-73431851-android-org.png/thumb?area=100&is_public=true)
2
劳瘁的米德尔顿
reacted to
3
1
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$ given that Genentech was acquired by Roche in 2009 for 46B and the strategic maneuvering that has been done with Lumiradx could we potentially see a 10er at least guess we will find out
3
3
劳瘁的米德尔顿
reacted to
$LumiraDx (LMDXF.US)$ In most situations companies will focus on 1 acquisition at a time in this case $Poseida Therapeutics(Delisted) (PSTX.US)$ for asset allocation the SPA document proves that we got held up through regulatory hurdles Genetech was a 46B deal from what I understand, so tell me again how $ROCHE HOLDING AG (RHHBY.US)$ isn't willing to throw money at stuff. pstx is set to finish on or by Wednesday, are we next? 🧐🧐🧐
4
1